Full Text View
Tabular View
No Study Results Posted
Related Studies
Response to GSK Biologicals’ Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
This study has been completed.
Study NCT00136604   Information provided by GlaxoSmithKline
First Received: August 26, 2005   Last Updated: June 12, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Diphtheria
Tetanus
Pertussis
Hepatitis B
Haemophilus Infections
Meningococcal Infections
Additional conditions recognized in this trial
Communicable Diseases
Hepatitis
Infection
Whooping Cough
More general conditions related to this trial
Actinomycetales Infections
Bacterial Infections
Bordetella Infections
Clostridium Infections
Corynebacterium Infections
Digestive System Diseases
DNA Virus Infections
Gram-Negative Bacterial Infections
Gram-Positive Bacterial Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Neisseriaceae Infections
Pasteurellaceae Infections
Respiratory Tract Diseases
Respiratory Tract Infections
Virus Diseases
Sponsors listed in this trial
GlaxoSmithKline


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services